ABSTRACT Objective: To analyze the drug use of paclitaxel injection and its related factors, and provide reference for clinical rational drug use. Methods:The medication status of 255 patients who took paclitaxel injection from March 2017 to November 2017 in a hospital were analyzed retrospectively, such as the dose, vehicle, paclitaxel dosage form, pre chemotherapy, chemotherapy, and the characteristics of adverse drug reactions(ADR) during medication. Its ADR carries out related factor analysis. Results:Paclitaxel (112 males and 143 females) with an average age of 56.6 years was used in 255 patients. The primary tumors were mainly non small cell lung cancer, ovarian malignant tumor and head and neck cancer. The tumor TNM stage was mainly stage Ⅳ. There were 44 cases (17.25%) of paclitaxel monotherapy and 211 cases (82.75%) of combination chemotherapy. The proportions of paclitaxel indications, dosages, and vehicles about off label drug uses were 53.72%, 20.54%, and 10.10%, respectively. The incidence of ADR was 81.96%, and severe ADR was 20.70% (94/454). The main ADR types were blood and lymphatic diseases and skeletal muscle and connective tissue, with the most common white blood cell count reduced (25.11%). Among them, gender, age, indications, vehicle, dose and chemotherapy regimen had no significant difference in the incidence of paclitaxel ADR. There were significant differences in the factors, including the department, the manufacturer and whether to take preventive medication. Conclusion:The paclitaxel injection in a hospital has off label drug uses. The results suggest that there is no correlation between the over instruction and ADR. The incidence of ADR in several combined chemotherapy regimens is not much different. The clinical selection of chemotherapy regimens may not require too much consideration for the difference in the incidence of ADR between the various chemotherapy regimens. The use of the liposome dosage form of paclitaxel may reduce the occurrence of ADR. |